Proteostasis Therapeutics, Inc. Exclusively Licenses Discoveries Related to Unfolded Protein Response from Ron Laboratory at New York University

Published: Jan 07, 2010

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Proteostasis Therapeutics announced today that it has entered into an exclusive license agreement with New York University for intellectual property related to discoveries from the laboratory of David Ron, M.D., Professor of Medicine and Julius Raynes Professor of Cell Biology at NYU Langone Medical Center’s Skirball Institute of Biomolecular Medicine. Dr. Ron’s research focuses on the Unfolded Protein Response (UPR) and his laboratory identifies new components of the cellular response to stress, which is the mechanism behind many common diseases of aging. The UPR is an important part of the Proteostasis Network (PN), the cellular machinery that maintains protein health. The exclusive license accelerates the Company’s drug discovery efforts to identify Proteostasis Regulators (PRs), small molecule drugs designed to restore protein balance. In addition, Dr. Ron has joined the Company’s Scientific Advisory Board.

Back to news